Lindsay Rosenwald

Last updated
Lindsay Rosenwald
Personal details
Alma mater Pennsylvania State University, Temple University
Occupation
  • Businessman
  • investor

Lindsay A. Rosenwald is an American doctor, biotechnology and life sciences industry investor. [1] He is the co-founder of the healthcare private equity firm Opus Point Partners. [2] Rosenwald has created and sold several biotechnological companies. In 2013 he established Fortress Biotech. [3]

Contents

Medicines his companies developed have been approved by the United States Food and Drug Administration as well as in foreign countries, such as Mexico or Canada. One medicine was approved for acute promyelocytic leukemia, a routinely fatal disease. This medicine has cured many thousands of incurable patients over the last decade, marking a significant change to how this disease is treated. One of his start-ups also developed a prostate cancer medicine. That company acquired $1 billion after Phase 2 studies. [4] Other approved medicines include meds for schizophrenia, fibromyalgia, obesity, influenza, and infant respiratory distress syndrome.

Early life

Rosenwald graduated from Abington Senior High School, located in southeast Pennsylvania, in 1973 and went on to graduate from Pennsylvania State University with a major in Finance and Economy in 1977, graduating Beta Gamma Sigma. Then he worked as an independent management consultant for healthcare companies from 1977 to 1979 before entering Temple University at their School of Medicine. After graduating from Temple in 1983, Rosenwald interned at Abington Medical Hospital and remained in private medical practice until 1986. At that time, he moved to Wall Street to serve as a physician and financial analyst. [5]

Career

In 1988, Lindsay A. Rosenwald became a managing director of corporate finance for D.H. Blair & Co., a privately owned investment firm headed by J. Morton Davis. D.H. Blair underwrote hundreds of companies, many in the biotechnology industry. Several D.H. Blair brokers were indicted for fraud, and the firm was shut down. Rosenwald headed a team of three physician-financiers who searched in the medical community for the latest developments that could be marketed with the help of private investment. They got in touch with hospitals, medical schools, pharmaceutical companies, universities, scientific firms and research groups. [6] [7]

In 1991, Rosenwald founded Paramount Bio Capital, where he dealt with the fields of bioresearch and biotechnology. Since 1992, he has become a NASD-member dealer. In 1995, Paramount Capital Investments LLC, a merchant and investment bank, was founded. Paramount Capital Asset Management, Inc., owned by Rosenwald, managed the investments of several funds specializing in the technology and biotechnology sectors [8] [9] [10] since 1994. Rosenwald also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Counsel. [11] [12]

Rosenwald was number one in the 2002 edition of Genetic Engineering News' 100 Molecular Millionaires. [13] [14] Since 2002, Rosenwald was in the board of directors for Keryx Biopharmaceuticals, Inc., which he resigned in 2006 to devote more time to the biotechnology market. [15]

Cougar Biotechnology, another company founded by Rosenwald, was purchased by Johnson & Johnson in 2009 based solely on abiraterone acetate. This drug was not yet in phase III clinical trials for its application in prostate cancer treatment and therapy but was so promising that Johnson & Johnson bid & purchased the company in a "short-term merger" for approximately $1 billion.

In addition to his activities, which have provided capital and funding to many portfolio companies, Rosenwald also started the Rosenwald Foundation. This nonprofit organization has provided millions of dollars to support various scientific and medical education institutions.

In 2009, Rosenwald and Michael S. Weiss founded a new company called OpusPoint Partners. [16] This company specializes in healthcare and life sciences investments and consulting. [17] In October 2010, he invested in securities in National Holdings Corporation purchasing approximately 23.6% of NHC. [18]

Related Research Articles

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, Genzyme and others.

Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.

Corporate venture capital (CVC) is the investment of corporate funds directly in external startup companies. CVC is defined by the Business Dictionary as the "practice where a large firm takes an equity stake in a small but innovative or specialist firm, to which it may also provide management and marketing expertise; the objective is to gain a specific competitive advantage." Examples of CVCs include GV and Intel Capital.

<span class="mw-page-title-main">Mitchell J. Blutt</span> American physician

Mitchell J. Blutt is an American physician-businessman. He is one of the first physicians to play a prominent role on Wall Street by drawing on his medical training to identify investment potential in healthcare companies. He is the founder and CEO of the New York-based healthcare investment firm, Consonance Capital, and a former Executive Partner of J.P. Morgan Partners. He is also a Clinical Assistant Professor of Medicine in the Department of Medicine at Weill Cornell Medicine and the Graduate School of Medical Sciences of Cornell University.

Matthew Chervenak is an American entrepreneur who has founded several businesses, a nonprofit, and hosts a YouTube Interview Series: Reforming Congress Conversations, on strengthening the US Congress. Chervenak founded and leads The Sunwater Institute, nonprofit nonpartisan public policy think tank, AllSci Corp, a business focused on improving scientific knowledge creation, and Sunwater Capital, an investment firm.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

OpusPoint Partners, LLC is an investment advisory firm specializing in healthcare and life sciences.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

<span class="mw-page-title-main">Syneos Health</span> Contract research organization

Syneos Health is an American company that provides contract research and commercial services to pharmaceutical and biotechnology companies. Based in Morrisville, North Carolina, the company specializes in helping other companies with late-stage clinical trials, but also provides commercial services to market health treatments.

Human Longevity, Inc. is a San Diego-based venture launched by Craig Venter and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

The New England Enzyme Center (NEEC) was created at the Tufts University School of Medicine in Boston, Massachusetts in 1964 as a federally supported biochemical resource center.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer. In October 2016, Michael Gilman, a former Biogen executive, was named CEO.

<span class="mw-page-title-main">Leerink Partners</span> U.S. investment bank

Leerink Partners LLC is an independent investment bank providing healthcare companies and investors with financial services including M&A advisory, equity and debt capital markets, proprietary research, and sales and trading capabilities. The firm was founded in 1995 by Jeffrey A. Leerink, and is headquartered in Boston, with offices in New York City, San Francisco, Charlotte, and Nashville.

<span class="mw-page-title-main">David Lucchino</span>

David L. Lucchino is co-founder and chief executive officer of Frequency Therapeutics, a biotechnology company based in Lexington, MA.

Joseph Edelman is an American hedge fund manager who founded Perceptive Advisors, a New York City-based hedge fund specializing in the healthcare sector and biotechnology. He helped take biotech firms public via the use of special-purpose acquisition companies.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

References

  1. ↑ Barbanel, Josh (2008-05-25). "Great Views, Priceless". The New York Times. ISSN   0362-4331 . Retrieved 2023-02-22.
  2. ↑ "OpusPoint Partners Team". OpusPoint Partners. Retrieved 4 February 2013.
  3. ↑ "Lindsay Rosenwald Is The Executive Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO) And They Just Picked Up 18% More Shares". simplywall.st. 2023-02-16. Retrieved 2023-05-22.
  4. ↑ "J&J Buys Cougar Biotechnology to Add Cancer Drugs". Lisa Rapaport and David Olmos. Bloomberg. May 22, 2009. Retrieved 4 February 2013.
  5. ↑ The New York Times: Business People
  6. ↑ Elizabeth M. Fowler (September 25, 1990). "Careers; Gaining New Perspectives On Medicine". The New York Times (Press release). Retrieved 2010-02-13.
  7. ↑ Lawrence J. DeMaria (June 26, 1988). "INVESTING; A Doctor's Favorite Medical Start-Ups". The New York Times (Press release). Retrieved 2010-02-13.
  8. ↑ Finance Club, Harvard University. Graduate School of Business Administration. Career Resources Center (August 28, 2008). Investment banking. Harvard Business School career guide. the University of California. Graduate School of Business Administration, Harvard University, 1990. pp. 35, 123. ISBN   978-0-87584-223-3.{{cite book}}: |author= has generic name (help)
  9. ↑ https://www.sec.gov/comments/s7-08-09/s70809-4614.pdf US Securities and Exchange Commission
  10. ↑ Max Abelson (April 14, 2009). "Never Mind the $100 M.: Doc Gets $75K in Rent for 15 CPW Duplex" (Press release). The New York Observer. Archived from the original on April 17, 2009.
  11. ↑ http://ps.cpmc.columbia.edu/annual/docs/annualreport01.pdf%5B%5D Columbia UniversityCollege of Physicians & Surgeons
  12. ↑ http://nyp.org/pdf/2005-2006_3_facts_financials.pdf NewYork-Presbyterian Hospital Advisory Councils
  13. ↑ Brian O'Neill (Apr 21, 1999). "Biotechnology Bay State has share of 'Molecular Millionaires'" (Press release). The Boston Globe. Archived from the original on June 4, 2011. Retrieved 2010-02-08. D.4
  14. ↑ Ronald Rosenberg, Globe Staff (Apr 9, 1997). "Molecular millionaires Interneuron executives top Massachusetts list" (Press release). The Boston Globe. Archived from the original on June 4, 2011. Retrieved 2010-02-08.
  15. ↑ "People". Nature Biotechnology. 24 (12): 1602. 2006. doi: 10.1038/nbt1206-1602 . S2CID   216086354.
  16. ↑ "OpusPoint Partners History". opuspointpartners.com. Retrieved 2011-06-13.
  17. ↑ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
  18. ↑ "Ventrus Biosciences Inc". finance.yahoo.com. May 26, 2011. Retrieved 2011-06-13.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.